Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

MYO vs NPCE: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

NPCE Wins Head-to-Head Institutional Verdict (4–1 across 6 Pillars · 8–2 Matrix Metrics)

NPCE Overall Winner 6-Pillar Tally: MYO 1 – 4 NPCE (1 Tie) Matrix Metrics: MYO 2 – 8 NPCE

As of Nov 20, 2026, Neuropace, Inc. (NPCE) is the stronger overall head-to-head candidate over Myomo Inc. (MYO) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). MYO carries a Unified Composite Score of 40.1/100 (SELL) at $0.81 (N/M Forward P/E, -21.8% operating margin), whereas NPCE carries 54.4/100 (HOLD) at $7.95 (91.7x Forward P/E, -9.6% operating margin).

  • Growth vs. Quality Trade-Off: NPCE earns the overall head-to-head edge with a stronger Unified Composite Score (54.4/100 HOLD vs. MYO 40.1/100 SELL) and 1.17β · 135% Vol risk profile, whereas MYO leads top-line expansion (+22.2% YoY revenue growth, N/M PEG, and 1 of 6 institutional pillars) for higher-beta growth mandates.
  • Technical & Structure Timing Caution: MYO is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 28.7); meanwhile NPCE is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 25.6). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About MYO vs NPCE
MYO NYSE American
Myomo Inc.
Orthopedic, Prosthetic & Surgical Appliances & Supplies
$0.81
-3.45% 1D
Market Cap $33.7M
TTM Revenue $46M
Forward P/E N/M
Beta / 30D Vol 2.22β · 107% Vol
Unified Composite Score
40.1 / 100 SELL
Tech 25.0 Fund 43.0 Flow 58.0 Mom 59.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -9.9%), weak momentum, RSI 29
RSI-14: 28.7 · SMA20: $1.16 · SMA50: $1.32
NPCE NASDAQ Head-to-Head Winner
Neuropace, Inc. Common Stock
Surgical & Medical Instruments & Apparatus
$7.95
-2.33% 1D
Market Cap $280.4M
TTM Revenue $107M
Forward P/E 91.7x
Beta / 30D Vol 1.17β · 135% Vol
Unified Composite Score
54.4 / 100 HOLD
Tech 55.0 Fund 61.0 Flow 67.0 Mom 73.9
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -9.1%), weak momentum, RSI 26
RSI-14: 25.6 · SMA20: $11.29 · SMA50: $12.57

6-Pillar Scorecard Institutional Category Breakdown (MYO 1 – 4 NPCE)

Columns: Metric · MYO · NPCE
1. Valuation Multiples NPCE
Forward P/E N/M 91.7x
Trailing P/E N/M 91.7x
PEG Ratio N/M N/M
EV / Revenue 0.9x 3.2x
2. Growth & Scale NPCE
Revenue Growth (YoY) +22.2% -1.1%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $46M $107M
Market Cap $33.7M $280.4M
3. Profitability & Quality NPCE
Gross Margin 70.1% 77.8%
Operating Margin -21.8% -9.6%
Net Profit Margin -33.1% -17.7%
Return on Equity (ROE) -173.5% -97.0%
4. Balance Sheet & Cash Flow NPCE
Cash Generation (TTM) -$9.1M -$12M
Cash Flow Margin -20.0% -11.6%
Net Cash / Leverage $8.9M Net Debt (3.44x D/E) $59M Net Debt (6.05x D/E)
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning MYO
Options Structure Phase UNCLASSIFIED BREAKDOWN
Current IV / %ile 266.0% (81st %ile) 59.9% (10th %ile)
Put/Call OI Skew N/A 0.38x (Call-Skewed)
OBV Trend / Tech Phase NEUTRAL · Markdown DISTRIBUTION · Markdown
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Medical Devices Operator Medical Devices Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: MYO (2) vs NPCE (8)
Institutional Metric MYO NPCE Criterion Row Edge
Market Capitalization
Scale
$33.7M $280.4M Larger Scale NPCE
Trailing P/E Ratio
Valuation
N/M 91.7x Lower Multiple NPCE
Forward P/E Ratio
Valuation
N/M 91.7x Lower Multiple NPCE
Revenue Growth (YoY)
Growth
+22.2% -1.1% Higher Growth MYO
Operating Margin (TTM)
Profitability
-21.8% -9.6% Higher Margin NPCE
Net Profit Margin
Profitability
-33.1% -17.7% Higher Margin NPCE
Return on Equity (ROE)
Capital Efficiency
-173.5% -97.0% Higher ROE NPCE
52-Week Range Position
Momentum
16% ($1–$2) 18% ($5–$20) Stronger Trend NPCE
Beta / 30D Volatility
Risk Regime
2.22β · 107% Vol 1.17β · 135% Vol Lower Realized Risk MYO
Unified Institutional Score
Composite Signal
40.1 / 100 (SELL) 54.4 / 100 (HOLD) Higher Composite NPCE
Trailing 12M Revenue (USD)
Operating Scale
$46M $107M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
70.1% 77.8% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 0.9x EV/Rev N/M PEG · 3.2x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$9.1M ($8.9M Net Debt (3.44x D/E)) -$12M ($59M Net Debt (6.05x D/E)) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon MYO +5.98 pp
MYO: -33.52% · NPCE: -39.5%
3M Horizon MYO +1.52 pp
MYO: -41.65% · NPCE: -43.17%
6M Horizon MYO +30.99 pp
MYO: -22.02% · NPCE: -53.01%
1Y Horizon MYO +55.92 pp
MYO: +12.3% · NPCE: -43.62%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period MYO Revenue NPCE Revenue MYO Op. Margin NPCE Op. Margin Margin Leader
FY2018 $0M N/A -430.8% N/A MYO
FY2019 $0M N/A -281.3% N/A MYO
FY2020 $10M $40M -138.5% -31.7% NPCE
FY2021 $10M $50M -74.1% -52.5% NPCE
FY2022 $20M $50M -68.6% -89.6% MYO
FY2023 $20M $70M -42.8% -41.5% NPCE
FY2024 $30M $80M -19.1% -27.1% MYO
FY2025 $40M $100M -35.2% -16.3% NPCE

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
MYO UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 266.0%
IV Percentile 81st %ile
Put/Call OI Skew N/A
IV Regime Extreme (>80th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact MYO Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
NPCE BREAKDOWN
137d in phase · OBV DISTRIBUTION
Current IV 59.9%
IV Percentile 10th %ile
Put/Call OI Skew 0.38x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow DISTRIBUTION
Exact NPCE Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
MYO Moat Profile Cyclical / Execution-Driven Positioning
Medical Devices Operator
Competes within the Medical Devices value chain with $33.7M market capitalization and -21.8% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
NPCE Moat Profile Cyclical / Execution-Driven Positioning
Medical Devices Operator
Competes within the Medical Devices value chain with $280.4M market capitalization and -9.6% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ MYO vs NPCE Key Questions & Quantitative Answers

As of Nov 20, 2026, Neuropace, Inc. (NPCE) is the stronger overall head-to-head candidate over Myomo Inc. (MYO) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). MYO carries a Unified Composite Score of 40.1/100 (SELL) at $0.81 (N/M Forward P/E, -21.8% operating margin), whereas NPCE carries 54.4/100 (HOLD) at $7.95 (91.7x Forward P/E, -9.6% operating margin). Growth vs. Quality Trade-Off: NPCE earns the overall head-to-head edge with a stronger Unified Composite Score (54.4/100 HOLD vs. MYO 40.1/100 SELL) and 1.17β · 135% Vol risk profile, whereas MYO leads top-line expansion (+22.2% YoY revenue growth, N/M PEG, and 1 of 6 institutional pillars) for higher-beta growth mandates. Technical & Structure Timing Caution: MYO is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 28.7); meanwhile NPCE is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 25.6). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

NPCE leads the Growth & Scale pillar: MYO posts +22.2% YoY revenue growth and +0.0% YoY earnings growth on $46M TTM revenue (70.1% gross margin, -21.8% operating margin), compared with NPCE at -1.1% YoY revenue growth and +0.0% YoY earnings growth on $107M TTM revenue (77.8% gross margin, -9.6% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), MYO cumulative revenue shifted +300.0% while NPCE shifted +150.0%. In operating R&D and SG&A reinvestment, MYO deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for NPCE.

NPCE screens cheaper on headline valuation multiples. MYO trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 0.9x EV/Revenue (-20.0% FCF margin), whereas NPCE trades at 91.7x Forward P/E, 91.7x Trailing P/E, N/M PEG, and 3.2x EV/Revenue (-11.6% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against MYO (-173.5% ROE) versus NPCE (-97.0% ROE) capital efficiency.

In options market volatility and institutional positioning, MYO carries 266.0% implied volatility (81st %ile, Extreme (>80th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (2.22β · 107% Vol realized risk). By comparison, NPCE carries 59.9% implied volatility (10th %ile, Compressed (<25th %ile)), a 0.38x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (1.17β · 135% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.